1-4 of 4
Christopher Walker
Close
Sort by
Journal Articles

BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment

Paolo Neviani, Ph.D, Jason G Harb, Ph.D, Joshua J Oaks, B.S., Christopher Walker, B.S., Ramasamy Santhanam, Ph.D, Carolyn Paisie, B.S., Anna Eiring, Ph.D, Bin Zhang, Ph.D, Bastianella Perazzona, Ph.D, Y. Ma, Charlene Mao, Guido Marcucci, MD, Tessa L. Holyoake, PhD, FRCP, FRCPath, Stefano Volinia, MD, Jorge E. Cortes, MD, Michael A. Caligiuri, MD, Claudia Huettner, Ph.D, Robert Bittman, Ph.D, Ching-Shih Chen, Ph.D, Ralph B. Arlinghaus, PhD, Peter Hokland, MD, DMSC, Denis-Claude Roy, MD, FRCPC, Ravi Bhatia, MD, Danilo Perrotti, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 515.
https://doi.org/10.1182/blood.V116.21.515.515
Published: 2010
Journal Articles

Pharmacologic Restoration of PP2A Activity and Interference with the SET-PP2A Interplay by FTY720 and Its Non-Immunosuppressive Derivative as a Novel and Efficient Therapy for Ph-Negative Myeloproliferative Disorders

Joshua J Oaks, A. Mukhopadhyay, Ramasamy Santhanam, S. A Saddoughi, Christopher Walker, Paolo Neviani, Jason G Harb, Y. Ma, Srdan Verstovsek, MD, PhD, Guido Marcucci, MD, Roger Briesewitz, Robert Bittman, Ching-Shih Chen, Alfonso Quintas-Cardama, MD, Besim Ogretmen, Danilo Perrotti, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 775.
https://doi.org/10.1182/blood.V116.21.775.775
Published: 2010
Journal Articles

PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives

Christopher Walker, B.S., Joshua J Oaks, B.S., Paolo Neviani, Ph.D, Jason G Harb, Ph.D., Ramasamy Santhanam, Ph.D, Y. Ma, Guido Marcucci, MD, James Van Brocklyn, Ph.D, Ching-Shih Chen, Ph.D, Robert Bittman, Ph.D, Danilo Perrotti, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 2901.
https://doi.org/10.1182/blood.V116.21.2901.2901
Published: 2010
Journal Articles

Ex Vivo Multiplexed Signal Pathway Inhibitor Treatment Reveals Differential Sensitivity of Myeloma and Non-Myeloma Bone Marrow Cell Populations.

Virginia Espina, MS, Alessandra Romano, MD, Amy VanMeter, BS, Gregory Orloff, MD, Alexander I. Spira, MD, PhD, Dipti Patel, MD, Christopher Walker, BS, Emanuel F Petricoin, III, PhD, Lance A Liotta, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 2860.
https://doi.org/10.1182/blood.V114.22.2860.2860
Published: 2009